CORT
BuyPremium GrowerAI neutralCorcept Therapeutics Incorporated · Healthcare · United States · $9.3B cap · $123.8M/day traded
$85.86 -20.1% · close 23 Oct · scored 24 Oct
StockRank down 5.7 since 23 Oct: Momentum down 6 after a 20% price fall.
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 4 Nov: the next-year EPS estimate has risen 37.4% over the last 14 weeks.
As of 24 Oct 2026, MoatMap's StockRank for Corcept Therapeutics Incorporated (CORT) is 67/100, ranked against 24,000+ stocks in 35 markets (Quality 74, Value 9, Momentum 79, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Corcept Therapeutics sells Korlym for Cushing's syndrome and has just received a positive CHMP opinion recommending EU approval for relacorilant (Lifyorli), which widens its commercial reach. Profitability and momentum are strong, but the stock scores very poorly on valuation, the company has announced a leadership transition, and insiders have been net sellers. Much of the value depends on relacorilant winning further approvals and on generic competition to Korlym.
ABOUT CORCEPT THERAPEUTICS INCORPORATED
Read
Corcept Therapeutics Incorporated is a pharmaceutical company specializing in the discovery and development of cortisol-modulating drugs, with Korlym approved for Cushing's syndrome. The company establishes a strong market position by addressing rare diseases with proprietary treatments. This niche focus and pipeline of selective cortisol modulators provide a competitive edge.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 401.9M | 482.4M | 675.0M | 761.4M | 23.7% | 830.8M | 1.1B | 1.7B | 49.7% |
| EPS | 0.95 | 1.02 | 1.35 | 0.95 | 0.0% | 0.45 | 0.94 | — | -0.6% |
| Shares | 107.8M | 103.4M | 105.1M | 106.0M | -1.7% | 108.1M | — | — | — |
| Debt | 1.1M | 0.2M | 6.9M | 6.1M | 74.8% | 9.4M | — | — | — |
| Equity | 501.8M | 506.7M | 679.6M | 647.8M | 8.9% | — | — | — | — |
| Op CF | 120.3M | 126.7M | 198.3M | 142.0M | 5.7% | 109.7M | — | — | — |
| Inv CF | -114.3M | 90.9M | -177.6M | 69.8M | — | — | — | — | — |
| Fin CF | -17.3M | -148.7M | -28.3M | -220.4M | — | — | — | — | — |
Above its 200-day average and 32% below its 52-week high.
Swung more than 90% of stocks we rank over the past year (83% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CORT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated(you) | $9.3B | 67 | Buy |
| KRYS | Krystal Biotech, Inc. | $9.2B | 67 | Buy |
| CAI | Caris Life Sciences, Inc. | $9.0B | 68 | Buy |
| PTGX | Protagonist Therapeutics, Inc. | $9.0B | 66 | Buy |
| TECH | Bio-Techne Corporation | $11.4B | 73 | Buy |
| LGND | Ligand Pharmaceuticals Incorporated | $6.1B | 71 | Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $10.8B | 57 | Hold |
| TGTX | TG Therapeutics, Inc. | $8.3B | 48 | Hold |
| TWST | Twist Bioscience Corporation | $9.3B | 43 | Hold |
| RPRX | Royalty Pharma plc | $36.9B | 65 | Buy |
Peer medians: ROE -31.5% · P/E 27.3x · Gross margin 62.6%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.